Update of MS Coalition’s DMT Paper Now Available
In August 2014, MSAA posted a news item announcing that the Multiple Sclerosis Coalition (MSC) had published a paper detailing the current evidence that supports the FDA-approved disease-modifying therapies (DMTs) for the long-term treatment of multiple sclerosis (MS). This paper was written expressly for healthcare providers and the health-insurance industry. Please note that the original version of this paper has since been updated to include two of the newer approvals: Lemtrada™ (alemtuzumab) and Plegridy™ (peginterferon beta-1a). To view this updated version, please see “The Use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence,” or go to www.ms-coalition.org/DMT. Printed copies of this publication will be available soon. Please check MSAA’s website for updates.
For background information on this paper, please see MSAA’s news item, “MSC Publishes Professional Consensus Paper on DMTs.”
Member organizations of the MSC also collaborated to develop a summary, written in a more reader-friendly style to better serve the broader MS community. This was published in November 2014 and does not yet include the newer approvals. For more information on the summary, please see MSAA’s news item, “MSC Publishes Summary Paper on DMTs.”